<DOC>
	<DOC>NCT00776009</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory classroom setting.</brief_summary>
	<brief_title>Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
	<criteria>Male and female subjects aged 612 years, inclusive. Subjects meeting the DSMIV criteria for primary diagnosis of ADHDCombined type, or predominantly hyperactiveimpulsive subtype, as established by the KSADSPL (Kiddie Schedule for Affective Disorders and SchizophreniaPresent and Lifetime Version). If a DSMIVdefined ADHD diagnosis is difficult to establish due to possible comorbidity, the subject will not be enrolled into the study. Subjects should be on a stabilized total daily dose or nearest equivalent of 4060 mg methylphenidate or 2030 mg of dmethylphenidate for at least two weeks prior to Screening visit. Subject or subject's guardian unable to understand or follow instructions necessary to participate in the study. Diagnosed with or history of a tic disorder or Tourette's syndrome. History of seizure disorder. The presence of a known medical condition that would preclude the use of methylphenidate. A history (within the past year) or presence of clinically significant cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease. ALT (Alanine Amino Transferase), AST (Aspartate Amino Transferase), GGT (Gamma glutamyl transferase) or serum creatinine greater then 2X the ULN (Upper Limit of Normal) at Screening. A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder) Subjects who have participated in an investigational trial within the past 4 weeks (28 days) Subjects who are currently taking antidepressants or other psychotropic medication. Subjects who have initiated psychotherapy during the three months prior to randomization. Subjects with a positive urine drug screen. Subjects who have a history of poor response or intolerance to methylphenidate or dmethylphenidate. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ADHD, children, subjects, laboratory classroom</keyword>
</DOC>